Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Wall Street analysts expect that Journavx, whose active ingredient is suzetrigine, could bring in about $100 million in sales this year. “We believe the opioid epidemic could be a priority for ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...